ethyl 3-(4-methoxy-3-(2-oxo-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)-1H-pyrazole-5-carboxylate | 1202645-22-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: ethyl 3-(4-methoxy-3-(2-oxo-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)-1H-pyrazole-5-carboxylate
• 英文别名: ethyl 3-[4-methoxy-3-[2-oxo-2-(5-pyridin-2-yl-3,4-dihydro-1H-isoquinolin-2-yl)acetyl]-1H-pyrrolo[2,3-c]pyridin-7-yl]-1H-pyrazole-5-carboxylate
• CAS: 1202645-22-4
• 化学式: C₃₀H₂₆N₆O₅
• 分子量: 550.574
• InChiKey: SLYHGKWHBGBXKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  41
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  143
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ethyl 3-(4-methoxy-3-(2-oxo-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)-1H-pyrazole-5-carboxylate 在 potassium carbonate 作用下， 以 甲醇 、 水 为溶剂， 反应 157.0h， 生成 3-(4-methoxy-3-(2-oxo-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)-N-methyl-1H-pyrazole-5-carboxamide trifluoroacetate
  参考文献：
  名称：

  Inhibitors of HIV-1 attachment: The discovery and structure–activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore

  摘要：

  6,6-Fused ring systems including tetrahydroisoquinolines and tetrahydropyrido[3,4-d]pyrimidines have been explored as possible replacements for the piperazine benzamide portion of the HIV-1 attachment inhibitor BMS-663068. In initial studies, the tetrahydroisoquinoline compounds demonstrate sub-nanomolar activity in a HIV-1 pseudotype viral infection assay used as the initial screen for inhibitory activity. Analysis of SARs and approaches to optimization for an improved drug-like profile are examined herein. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.11.009
• 作为产物：
  描述：

  5-溴-3,4-二氢-1H-异喹啉-2-羧酸叔丁酯 在 四(三苯基膦)钯 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 158.0h， 生成 ethyl 3-(4-methoxy-3-(2-oxo-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)-1H-pyrazole-5-carboxylate
  参考文献：
  名称：

  Inhibitors of HIV-1 attachment: The discovery and structure–activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore

  摘要：

  6,6-Fused ring systems including tetrahydroisoquinolines and tetrahydropyrido[3,4-d]pyrimidines have been explored as possible replacements for the piperazine benzamide portion of the HIV-1 attachment inhibitor BMS-663068. In initial studies, the tetrahydroisoquinoline compounds demonstrate sub-nanomolar activity in a HIV-1 pseudotype viral infection assay used as the initial screen for inhibitory activity. Analysis of SARs and approaches to optimization for an improved drug-like profile are examined herein. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.11.009
• 作为试剂：
  描述：

  1-(7-bromo-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethane-1,2-dione 、 5-三丁基锡烷基-1H-吡唑-3-羧酸乙酯 在 四(三苯基膦)钯 氮气 、 crude mixture 、 甲醇 、 乙醚 、 ethyl 3-(4-methoxy-3-(2-oxo-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)-1H-pyrazole-5-carboxylate 作用下， 以 1,4-二氧六环 为溶剂， 反应 17.0h， 以The expected product, ethyl 3-(4-methoxy-3-(2-oxo-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)-1H-pyrazole-5-carboxylate (0.17 g, 0.309 mmol, 30.3% yield), was isolated as a light-brown solid的产率得到ethyl 3-(4-methoxy-3-(2-oxo-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)-1H-pyrazole-5-carboxylate
  参考文献：
  名称：

  Diketopiperidine Derivatives as HIV Attachment Inhibitors

  摘要：

  本文提供了具有药物和生物影响特性的化合物、它们的制药组合物和使用方法。特别地，提供了具有独特的抗病毒活性的二酮亚胺衍生物。这些化合物对于治疗艾滋病毒和艾滋病非常有用。

  公开号：

  US20090325985A1

文献信息

• [EN] DIKETOPIPERIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS<br/>[FR] DÉRIVÉS DE LA DICÉTOPIPÉRIDINE UTILISÉS COMME INHIBITEURS DE FIXATION DU VIH
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009158396A1

  公开（公告）日：2009-12-30

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketopiperidine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物影响特性的化合物，其药物组合物和使用方法已经列出。具体来说，提供了具有独特抗病毒活性的二酮哌啶衍生物。这些化合物对治疗艾滋病毒和艾滋病非常有用。
• Diketopiperidine derivatives as HIV attachment inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US08242124B2

  公开（公告）日：2012-08-14

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketopiperidine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.

  本文提供了具有药物和生物影响特性的化合物、它们的制药组合物和使用方法。特别提供了具有独特抗病毒活性的二酮哌啶衍生物。这些化合物对治疗艾滋病毒和艾滋病有用。
• DIKETOPIPERIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2313408B1

  公开（公告）日：2012-07-11
• US8242124B2
  申请人：——

  公开号：US8242124B2

  公开（公告）日：2012-08-14
• Inhibitors of HIV-1 attachment: The discovery and structure–activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore
  作者：Jacob J. Swidorski、Zheng Liu、Zhiwei Yin、Tao Wang、David J. Carini、Sandhya Rahematpura、Ming Zheng、Kim Johnson、Sharon Zhang、Pin-Fang Lin、Dawn D. Parker、Wenying Li、Nicholas A. Meanwell、Lawrence G. Hamann、Alicia Regueiro-Ren

  DOI：10.1016/j.bmcl.2015.11.009

  日期：2016.1

  6,6-Fused ring systems including tetrahydroisoquinolines and tetrahydropyrido[3,4-d]pyrimidines have been explored as possible replacements for the piperazine benzamide portion of the HIV-1 attachment inhibitor BMS-663068. In initial studies, the tetrahydroisoquinoline compounds demonstrate sub-nanomolar activity in a HIV-1 pseudotype viral infection assay used as the initial screen for inhibitory activity. Analysis of SARs and approaches to optimization for an improved drug-like profile are examined herein. (C) 2015 Elsevier Ltd. All rights reserved.